Targeting EPO/EPOR axis in cancer: advances and challenges in nano-enabled delivery

The immunosuppressive tumor microenvironment (TME) is a major obstacle to effective cancer immunotherapy by promoting immune evasion and disease progression. Recent studies suggest that erythropoietin (EPO), a glycoprotein hormone traditionally associated with erythropoiesis, also functions as an emerging regulator of tumor immune remodeling in a context-dependent manner. Tumor-derived EPO can influence tumor-associated macrophages and type 1 conventional dendritic cells by engaging with the erythropoietin receptor (EPOR) expressed on those immune cell surfaces, thereby reshaping the immunosuppressive TME and facilitating immune escape. Targeting the EPO/EPOR axis has therefore emerged as a promising strategy for cancer immunotherapy, with anti-EPOR neutralizing antibodies, siRNA silencing and antagonists yielding encouraging preclinical efficacy. Nevertheless, clinical translation remains challenging because of the essential physiological role of EPO/EPOR signaling in erythropoiesis, potential off-target toxicity, and the difficulty of selectively blocking pathological signaling while preserving normal hematopoietic function. Nano delivery systems provide new opportunities for precise modulation of the EPO/EPOR axis by improving targeting specificity and minimizing systemic toxicity. This review systematically examines the evolving understanding of the EPO/EPOR axis in tumor immunity, discusses the advances and limitations of current targeting strategies, and highlights the opportunities of nano delivery systems for precision targeting of the EPO/EPOR axis in cancer immunotherapy.

Authors

Institutions

Publication Details

Journal
Journal of Nanobiotechnology
Published
2026-11-19
DOI
https://doi.org/10.1186/s12951-026-05235-y
Primary Topic
Erythropoietin and Anemia Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Targeting EPO/EPOR axis in cancer: advances and challenges in nano-enabled delivery

Yan Hu, Jiayi Sun, Xuesha Xing, Wei Jiang et al.
Journal of Nanobiotechnology
Erythropoietin and Anemia Treatment
article

Targeting EPO/EPOR axis in cancer: advances and challenges in nano-enabled delivery

Yan Hu, Jiayi Sun, Xuesha Xing, Wei Jiang, Qiang Liu, Mingrui Dai
article en

Abstract

The immunosuppressive tumor microenvironment (TME) is a major obstacle to effective cancer immunotherapy by promoting immune evasion and disease progression. Recent studies suggest that erythropoietin (EPO), a glycoprotein hormone traditionally associated with erythropoiesis, also functions as an emerging regulator of tumor immune remodeling in a context-dependent manner. Tumor-derived EPO can influence tumor-associated macrophages and type 1 conventional dendritic cells by engaging with the erythropoietin receptor (EPOR) expressed on those immune cell surfaces, thereby reshaping the immunosuppressive TME and facilitating immune escape. Targeting the EPO/EPOR axis has therefore emerged as a promising strategy for cancer immunotherapy, with anti-EPOR neutralizing antibodies, siRNA silencing and antagonists yielding encouraging preclinical efficacy. Nevertheless, clinical translation remains challenging because of the essential physiological role of EPO/EPOR signaling in erythropoiesis, potential off-target toxicity, and the difficulty of selectively blocking pathological signaling while preserving normal hematopoietic function. Nano delivery systems provide new opportunities for precise modulation of the EPO/EPOR axis by improving targeting specificity and minimizing systemic toxicity. This review systematically examines the evolving understanding of the EPO/EPOR axis in tumor immunity, discusses the advances and limitations of current targeting strategies, and highlights the opportunities of nano delivery systems for precision targeting of the EPO/EPOR axis in cancer immunotherapy.

Journal of Nanobiotechnology
Dalian University of Technology (CN), Dalian Municipal Central Hospital (CN)
Erythropoietin and Anemia Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon